Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolinapant + Decitabine/Cedazuridine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05403450Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of tolinapant in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Taiho Oncology. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Serious Adverse Events and Dose Limiting Toxicities up to 54 months and Overall Response Rate up to 54 months. Started Feb 2023; status: terminated.
02
Drugs
tolinapant
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05403450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403450.